Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IMNN vs GRML: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

IMNN Wins Head-to-Head Institutional Verdict (4–0 across 6 Pillars · 7–3 Matrix Metrics)

IMNN Overall Winner 6-Pillar Tally: IMNN 4 – 0 GRML (2 Tie) Matrix Metrics: IMNN 7 – 3 GRML

As of Nov 16, 2026, Imunon, Inc. (IMNN) is the stronger overall head-to-head candidate over GRML (GRML) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IMNN carries a Unified Composite Score of 32.2/100 (SELL) at $0.56 (16.8x Forward P/E, 0.0% operating margin), whereas GRML carries 56.8/100 (HOLD) at $3.51 (N/M Forward P/E, N/A operating margin).

  • Composite vs. Pillar Nuance: While GRML currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. IMNN 32.2/100 SELL), IMNN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY).
  • Technical & Structure Timing Caution: IMNN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile GRML trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IMNN vs GRML
IMNN NASDAQ Head-to-Head Winner
Imunon, Inc. Common Stock
Pharmaceutical Preparations
$0.56
-10.95% 1D
Market Cap $3.6M
TTM Revenue $125,000
Forward P/E 16.8x
Beta / 30D Vol 0.44β · 145% Vol
Unified Composite Score
32.2 / 100 SELL
Tech 25.0 Fund 42.0 Flow 50.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -19.8%), weak momentum, RSI 26
RSI-14: 26.1 · SMA20: $0.90 · SMA50: $1.13
GRML US Equity
GRML
Institutional Equity
$3.51
-2.77% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -5.32β · 95% Vol
Unified Composite Score
56.8 / 100 HOLD
Tech 60.0 Fund 57.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 37
RSI-14: 37.5 · SMA20: $4.67 · SMA50: $6.11

6-Pillar Scorecard Institutional Category Breakdown (IMNN 4 – 0 GRML)

Columns: Metric · IMNN · GRML
1. Valuation Multiples IMNN
Forward P/E 16.8x N/M
Trailing P/E 16.8x N/M
PEG Ratio 5.03x N/M
EV / Revenue N/M N/M
2. Growth & Scale IMNN
Revenue Growth (YoY) +0.0% N/A
Earnings Growth (YoY) +0.0% N/A
TTM Revenue (USD) $125,000 N/A
Market Cap $3.6M N/A
3. Profitability & Quality IMNN
Gross Margin N/A N/A
Operating Margin 0.0% N/A
Net Profit Margin 0.0% N/A
Return on Equity (ROE) -429.7% N/A
4. Balance Sheet & Cash Flow IMNN
Cash Generation (TTM) -$15M EBITDA N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage $3.9M Net Cash N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markdown NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IMNN (7) vs GRML (3)
Institutional Metric IMNN GRML Criterion Row Edge
Market Capitalization
Scale
$3.6M N/A Larger Scale IMNN
Trailing P/E Ratio
Valuation
16.8x N/M Lower Multiple IMNN
Forward P/E Ratio
Valuation
16.8x N/M Lower Multiple IMNN
Revenue Growth (YoY)
Growth
+0.0% N/A Higher Growth IMNN
Operating Margin (TTM)
Profitability
0.0% N/A Higher Margin IMNN
Net Profit Margin
Profitability
0.0% N/A Higher Margin IMNN
Return on Equity (ROE)
Capital Efficiency
-429.7% N/A Higher ROE IMNN
52-Week Range Position
Momentum
2% ($0–$4) 19% ($0–$18) Stronger Trend GRML
Beta / 30D Volatility
Risk Regime
0.44β · 145% Vol -5.32β · 95% Vol Lower Realized Risk GRML
Unified Institutional Score
Composite Signal
32.2 / 100 (SELL) 56.8 / 100 (HOLD) Higher Composite GRML
Trailing 12M Revenue (USD)
Operating Scale
$125,000 N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
5.03x PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$15M EBITDA ($3.9M Net Cash) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon GRML +3.59 pp
IMNN: -45.09% · GRML: -41.5%
3M Horizon GRML +1831.57 pp
IMNN: -64.55% · GRML: +1767.02%
6M Horizon GRML +969.27 pp
IMNN: -75.22% · GRML: +894.05%
1Y Horizon GRML +732.16 pp
IMNN: -82.16% · GRML: +650.0%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IMNN vs GRML. Trailing 12-month operating profitability (IMNN 0.0% vs GRML N/A) and valuation multiples (IMNN 16.8x vs GRML N/M Forward P/E) are benchmarked directly in Pillar 4 below.

IMNN ADR TTM Benchmark FX-Normalized USD
TTM Revenue$125,000
Gross MarginN/A
Op. Margin0.0%
ROE / Fwd P/E-429.7% · 16.8x
GRML ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IMNN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IMNN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
GRML UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact GRML Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IMNN Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $3.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
GRML Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IMNN vs GRML Key Questions & Quantitative Answers

As of Nov 16, 2026, Imunon, Inc. (IMNN) is the stronger overall head-to-head candidate over GRML (GRML) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). IMNN carries a Unified Composite Score of 32.2/100 (SELL) at $0.56 (16.8x Forward P/E, 0.0% operating margin), whereas GRML carries 56.8/100 (HOLD) at $3.51 (N/M Forward P/E, N/A operating margin). Composite vs. Pillar Nuance: While GRML currently prints a higher short-term Unified Composite Score (56.8/100 HOLD vs. IMNN 32.2/100 SELL), IMNN captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–0 across the 6 pillars) due to superior fundamental profitability (0.0% vs. N/A operating margin) and revenue trajectory (+0.0% vs. N/A YoY). Technical & Structure Timing Caution: IMNN is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 26.1); meanwhile GRML trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 37.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IMNN leads the Growth & Scale pillar: IMNN posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $125,000 TTM revenue (N/A gross margin, 0.0% operating margin), compared with GRML at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, IMNN generates $125,000 in USD-normalized revenue versus N/A for GRML. In operating R&D and SG&A reinvestment, IMNN deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for GRML.

IMNN screens cheaper on headline valuation multiples. IMNN trades at 16.8x Forward P/E, 16.8x Trailing P/E, 5.03x PEG, and N/M EV/Revenue (unreported EBITDA margin), whereas GRML trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IMNN (-429.7% ROE) versus GRML (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, IMNN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.44β · 145% Vol realized risk). By comparison, GRML carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-5.32β · 95% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.